Authors: Fazal A. Danish, Salman S. Koul, Fazal R. Subhani, Ahmed Ehsan Rabbani, 5. Saeeda Yasmin
Abstract
Decompensated cirrhosis has traditionally been considered a contraindication to interferon and ribavirin therapy. Whereas, the same may be true for advanced cirrhosis, which is only amenable to liver transplantation, there are reports in the literature in which antiviral therapy has been given in selected cases of early hepatic decompensation with reasonable results. Thus decompensation per se is no more an absolute contraindication to antiviral therapy. It, however, requires modifications in the dose regimen and close monitoring especially for the development of hematologic effects. In this article, the pros and cons of antiviral therapy in decompensated liver cirrhosis is given with special emphasis on how to avoid antiviral dose reductions/withdrawal secondary to the development of hematologic side effects by using hematopoietic growth factors (HGFs). At the end, suggested recommendations are given.
Keywords: Chronic hepatitis C. Decompensated Cirrhosis. Antiviral Therapy. Hematopoietic Growth Factors.
